SGR-2921

A First-In-Human, Phase 1, Dose Escalation Study of SGR-2921 as Monotherapy In Subjects With Relapsed/Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome

What's the purpose of the trial?

The purpose of this study is to evaluate safety and tolerability and to determine the maximum tolerated dose (MTD) and/or recommended dose (RD) of SGR-2921.
Trial status

Accepting patients

Phase
Phase 1
Enrollment
50
Last Updated
1 month ago
Am I Eligible

Participating Centers

There are 18 centers participating in this trial. Enter a location below to find the closest center.

Experimental Treatments

Learn more about the experimental treatments being evaluated in this clinical trial.

  • SGR-2921 is a CDC7 small molecule inhibitor that is being studied for use in several different indications. 

Arms / Cohorts

Explore eligibility, treatments and learn more about potential cohorts.

Accepting patients

SGR-2921

Accepting patients

SGR-2921

Real People. Real Support.

Need help connecting with this clinical trial? We're here to help!

Print Report

Print this trial to share with your doctor.

(888) 803-1766

We can help answer any questions and connect you (or your patient) with the study team.

Schedule Call

Schedule a time that is convenient and we’ll call you to see how we can help you and your patient.